Trial Profile
Phase IIa Study of Nimotuzumab in Second or Late- Line Treatment of Patients With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinomas
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 30 Nov 2013 New trial record